Stockreport

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression Further analysis of PARADIGM is on [Read more]